Home
Our Science
Our Pipeline
Partnering
Investors
Our Company
PR – ObsEva Publications – Media – Events
Contact

Skip to content

Our Company
PR – ObsEva Publications – Media – Events
Contact

Search

Skip to content

Home
Our Science
Our Pipeline
- Overview
- Nolasiban
- Linzagolix
- OBE022
Partnering
Investors

Our Science

Recent Posts

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
Babies Born Following Administration of Nolasiban Before Embryo Transfer (ET) After IVF: Neonatal and Infant Development Outcomes From a Double-Blind, Placebo-Controlled, Clinical Trial
Long Term Treatment of Endometriosis Associated Pain (EAP) With Linzagolix: Efficacy and Safety After 12 Months of Treatment
ObsEva to participate in Cantor Global Healthcare Conference October 2-4 2019

Recent Comments

Archives

Categories

Meta

Log in
Entries RSS
Comments RSS
WordPress.org

Our Science
Our Pipeline
Partnering
Investors

Our Company
ObsEva Publications
Press Releases
Contact:

Follow us on LinkedIn

Sign up for news

Copyright © 2019 ObsEva - All rights reserved.

Terms - Privacy Policy